February 23, 2018

February 23, 2018

Legal lion Barry Cohen reveals leukemia and tells how it has changed his priorities

Tampa Bay Times – Feb. 23

Cohen should have been in court Thursday, too, but the doors of his law firm were shuttered, his case notes in the hands of another attorney. Instead, the 78-year-old spends many of his days in bed at his Hyde Park home watching CNN or at the Moffitt Cancer Center.

Chemotherapy patients preserving hair through DigniCap cooling cap

WFTS – Feb. 21

That choice was given to Kerry by the DigniCap. It’s the first and only FDA-cleared scalp cooling system for patients undergoing chemo therapy to reduce hair loss. Kinsella is one of the first 20 patients at Moffitt Cancer Center in Tampa who is using the cap.

Optimizing Allogeneic Transplant Strategies in ALL

OncLive – Feb. 21

Bijal D. Shah, MD: I think that’s what the data support in T-cell ALL—taking both genomic risk and MRD into account when making decisions, and in that case, the ICD-10 classification scheme—but also in B-cell ALL. 

Acupuncture to help ease cancer treatment

WJRT – Feb. 21

She started with weekly treatments and continues it now once every three weeks. Acupuncturist, Liem Quang Le, DAOM, H. Lee Moffitt Cancer Center says it stimulates the body’s natural ability to heal itself.

PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10

Nasdaq – Feb. 22

Prior preclinical work by Moffitt Cancer Center established that PV-10 has therapeutic activity in pancreatic cancer murine models as both a single agent and in combination with gemcitabine, a standard chemotherapeutic agent used to treat this disease.

Durvalumab Approved by FDA for Reducing NSCLC Progression

The Africom – Feb. 21

"The PACIFIC trial data supporting today's approval of Imfinzi will change how we treat these patients", Scott Antonia of the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida and investigator in the PACIFIC trial, said. Also posted to Clinical Oncology News

Up-front Approaches to Treating Ph-Negative ALL

OncLive – Feb. 19

Bijal D. Shah, MD: I have the dubious task of pushing back against every member of the group as it relates to this transition to intensified pediatric regimens. I don’t agree. In fact, I’ve not seen any data to tell me that an intensified pediatric regimen is superior to hyper-CVAD. It’s not to say that intensified pediatric therapies are the wrong approach. Certainly, if a patient can tolerate the asparaginase-based regimen, I have no ill will towards anyone who gives a pediatric regimen.

NGS Testing Hits Clinical Practice

OncLive – Feb. 19

At Moffitt Cancer Center in Tampa, Florida, pathologists began developing larger panels when it became necessary to test for multiple abnormalities in non–smallcell lung cancer (NSCLC), including EGFR, KRAS, ALK, and ROS1, said Anthony M. Magliocco, MD, FRCPC, FCAP, chair of the Department of Anatomic Pathology at Moffitt.

USDA approves AstraZeneca lung cancer drug

Delaware Business Times – Feb. 19

Until now, treatment guidelines have recommended that patients with unresectable Stage III lung cancer undergo a period of active surveillance following chemoradiation therapy until disease progression,” said Scott J. Antonia, M.D., Ph.D., chair of the Thoracic Oncology Department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. Also posted to EPM Magazine, Financial Times, News Dog, Milenio, PharmaBiz, Pharmacy Choice, eCancer

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers

Nature – Feb. 19

Diagnostic bone marrow or peripheral blood aspirates were obtained from a total of 6 patients with CMML and 2 patients with AML. This includes 5 patients with CMML who were treated at the Memorial Sloan Kettering Cancer Center (MSKCC) and 1 from the Moffitt Cancer Center as well as 2 patients with AML treated at the MSKCC. 

US clears AZ’ Imfinzi for lung cancer

PharmaTimes – Feb. 19

Given that up to 89 percent of patients with Stage III NSCLC will progress to metastatic disease, “it is important that there is now a new option that can give patients more time without disease progression,” said Scott Antonia, chair of the Thoracic Oncology Department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa and investigator in the PACIFIC trial.

AstraZeneca's Imfinzi clears another FDA hurdle

London South East - Feb. 19

Scott Antonia, chair of the thoracic oncology department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa and investigator in the PACIFIC trial, said that until now, treatment guidelines recommended that patients with unresectable Stage III lung cancer undergo a period of active surveillance following chemoradiation therapy until disease progression.

FDA approves imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer

Medical Dialogues – Feb. 18

Scott J. Antonia, M.D., Ph.D., Chair of Thoracic Oncology Department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida and investigator in the PACIFIC trial said: “until now, treatment guidelines have recommended that patients with unresectable  Stage III lung cancer undergo a period of active surveillance following chemoradiation therapy until disease progression. Also posted to Pharmaceutical Daily News, ResearchTree.

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.